SAN RAFAEL, Calif., Oct. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich BioMarin's pipeline, which drives the future growth of the company. Dr. Cardon's promotion to lead BioMarin's scientific strategy is effective immediately.
"We are thrilled to promote Lon into the leadership role for our scientific strategy at BioMarin. BioMarin is committed to pioneering breakthrough science that has the potential to make a big impact on rare patient populations. Lon will support our company's growth by identifying the right balance of resources within BioMarin to move the most promising molecules through our pipeline," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer. "Lon has done an outstanding job of building our research capabilities positioning BioMarin for future success and brings his knowledge in genetics and drug discovery generally, and specifically in BioMarin's scientific expertise to this role."
In this newly created leadership position, Dr. Cardon's responsibilities expand beyond the Research functions at BioMarin and now include oversight of the company's product portfolio. He will lead cross functional activities to build our leadership position in precision medicine in support of patients with rare genetic diseases and drive long-term growth through the oversight of an exceptional pipeline of first- or best-in-class therapies.
"I have worked closely with Lon over the past two years and have the utmost confidence in his abilities to oversee a critical part of our business that drives our future growth," said Hank Fuchs, M.D., President, Worldwide Research and Development. "He is uniquely qualified to champion science at BioMarin that has the potential to change the practice of medicine and to bring together cross functional teams that will deliver potentially life-changing medicine to patients with rare diseases."
Previously, Dr. Cardon was Senior Vice President of Alternative Discovery and Development, and Head of Target Sciences at GlaxoSmithKline plc (GSK). During his nine years at GSK, he led platform groups in genetics, statistics, bioinformatics, epidemiology and clinical pharmacology and created a new division for exploratory therapeutic areas and platforms, including rare diseases, gene therapy, ophthalmology, women's health and others. Dr. Cardon was a longstanding member of GSK's R&D executive team, ultimately chairing their discovery board which governed the scientific direction of all of GSK's preclinical to phase 2 programs.
Before moving into the industry, Dr. Cardon was a professor of Biostatistics at the University of Washington and full member of the Fred Hutchinson Cancer Research Centre. Prior to that he was a professor and Wellcome Trust Principal Fellow at the University of Oxford. He received his PhD from the University of Colorado, Boulder and did his postdoctoral training at Stanford University. He is an elected Fellow of the UK's Academy of Medical Sciences and the American Association for the Advancement of Science.
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com. Information on such website is not incorporated by reference into this press release.
BioMarin® is a registered trademarks of BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
SOURCE BioMarin Pharmaceutical Inc.